

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07K 3/00, C07H 15/12 C12P 21/06</b>		<b>A1</b>	(11) International Publication Number: <b>WO 92/03470</b>
			(43) International Publication Date: 5 March 1992 (05.03.92)
(21) International Application Number: <b>PCT/US91/06140</b>		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(22) International Filing Date: 28 August 1991 (28.08.91)		Published With international search report.	
(30) Priority data: 574,613 28 August 1990 (28.08.90) US 577,392 31 August 1990 (31.08.90) US			
(71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).			
(72) Inventors: KIEFER, Michael, C. ; 401 Wright Court, Clayton, CA 94517 (US). MASIARZ, Frank ; 148 Marview Way, San Francisco, CA 94131 (US).			
(74) Agents: NEELEY, Richard, L. et al.; Cooley Godward Castro Huddleson & Tatum, Five Palo Alto Square, 4th Floor, Palo Alto, CA 94306 (US).			

(54) Title: GENETIC MATERIAL ENCODING IGFBP-5.

## (57) Abstract

A purified binding protein selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence which is at least 85 % homologous to the amino sequence and fragments thereof comprising at least 10 consecutive amino acids of the sequence that are capable of binding to an antibody specific for the protein or to an insulin-like growth factor is described. Recombinant DNA molecules encoding the binding proteins and subsequences thereof are also described along with recombinant microorganisms and cell lines containing the DNA molecules and methods for preparing the binding proteins by growing the recombinant hosts containing the relevant DNA molecules. Antibodies to the protein, identified as IGFBP-5, which are useful in various diagnostic applications, are also described.

DNA AND AMINO ACID SEQUENCE OF CLONE ENCODING IGFBP-5

1  
GATTCGAGCTCTACAGGCTT  
15  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
250  
260  
270  
280  
290  
300  
310  
320  
330  
340  
350  
360  
370  
380  
390  
400  
410  
420  
430  
440  
450  
460  
470  
480  
490  
500  
510  
520  
530  
540  
550  
560  
570  
580  
590  
600  
610  
620  
630  
640  
650  
660  
670  
680  
690  
700  
710  
720  
730  
740  
750  
760  
770  
780  
790  
800  
810  
820  
830  
840  
850  
860  
870  
880  
890  
900  
910  
920  
930  
940  
950  
960  
970  
980  
990  
1000  
1010  
1020  
1030  
1040  
1050  
1060  
1070  
1080  
1090  
1100  
1110  
1120  
1130  
1140  
1150  
1160  
1170  
1180  
1190  
1200  
1210  
1220  
1230  
1240  
1250  
1260  
1270  
1280  
1290  
1300  
1310  
1320  
1330  
1340  
1350  
1360  
1370  
1380  
1390  
1400  
1410  
1420  
1430  
1440  
1450  
1460  
1470  
1480  
1490  
1500  
1510  
1520  
1530  
1540  
1550  
1560  
1570  
1580  
1590  
1600  
1610  
1620  
1630  
1640  
1650  
1660  
1670  
1680  
1690  
1700  
1710  
1720  
1730  
1740  
1750  
1760  
1770  
1780  
1790  
1800  
1810  
1820  
1830  
1840  
1850  
1860  
1870  
1880  
1890  
1900  
1910  
1920  
1930  
1940  
1950  
1960  
1970  
1980  
1990  
2000  
2010  
2020  
2030  
2040  
2050  
2060  
2070  
2080  
2090  
2100  
2110  
2120  
2130  
2140  
2150  
2160  
2170  
2180  
2190  
2200  
2210  
2220  
2230  
2240  
2250  
2260  
2270  
2280  
2290  
2300  
2310  
2320  
2330  
2340  
2350  
2360  
2370  
2380  
2390  
2400  
2410  
2420  
2430  
2440  
2450  
2460  
2470  
2480  
2490  
2500  
2510  
2520  
2530  
2540  
2550  
2560  
2570  
2580  
2590  
2600  
2610  
2620  
2630  
2640  
2650  
2660  
2670  
2680  
2690  
2700  
2710  
2720  
2730  
2740  
2750  
2760  
2770  
2780  
2790  
2800  
2810  
2820  
2830  
2840  
2850  
2860  
2870  
2880  
2890  
2900  
2910  
2920  
2930  
2940  
2950  
2960  
2970  
2980  
2990  
3000  
3010  
3020  
3030  
3040  
3050  
3060  
3070  
3080  
3090  
3100  
3110  
3120  
3130  
3140  
3150  
3160  
3170  
3180  
3190  
3200  
3210  
3220  
3230  
3240  
3250  
3260  
3270  
3280  
3290  
3300  
3310  
3320  
3330  
3340  
3350  
3360  
3370  
3380  
3390  
3400  
3410  
3420  
3430  
3440  
3450  
3460  
3470  
3480  
3490  
3500  
3510  
3520  
3530  
3540  
3550  
3560  
3570  
3580  
3590  
3600  
3610  
3620  
3630  
3640  
3650  
3660  
3670  
3680  
3690  
3700  
3710  
3720  
3730  
3740  
3750  
3760  
3770  
3780  
3790  
3800  
3810  
3820  
3830  
3840  
3850  
3860  
3870  
3880  
3890  
3900  
3910  
3920  
3930  
3940  
3950  
3960  
3970  
3980  
3990  
4000  
4010  
4020  
4030  
4040  
4050  
4060  
4070  
4080  
4090  
4100  
4110  
4120  
4130  
4140  
4150  
4160  
4170  
4180  
4190  
4200  
4210  
4220  
4230  
4240  
4250  
4260  
4270  
4280  
4290  
4300  
4310  
4320  
4330  
4340  
4350  
4360  
4370  
4380  
4390  
4400  
4410  
4420  
4430  
4440  
4450  
4460  
4470  
4480  
4490  
4500  
4510  
4520  
4530  
4540  
4550  
4560  
4570  
4580  
4590  
4600  
4610  
4620  
4630  
4640  
4650  
4660  
4670  
4680  
4690  
4700  
4710  
4720  
4730  
4740  
4750  
4760  
4770  
4780  
4790  
4800  
4810  
4820  
4830  
4840  
4850  
4860  
4870  
4880  
4890  
4900  
4910  
4920  
4930  
4940  
4950  
4960  
4970  
4980  
4990  
5000  
5010  
5020  
5030  
5040  
5050  
5060  
5070  
5080  
5090  
5100  
5110  
5120  
5130  
5140  
5150  
5160  
5170  
5180  
5190  
5200  
5210  
5220  
5230  
5240  
5250  
5260  
5270  
5280  
5290  
5300  
5310  
5320  
5330  
5340  
5350  
5360  
5370  
5380  
5390  
5400  
5410  
5420  
5430  
5440  
5450  
5460  
5470  
5480  
5490  
5500  
5510  
5520  
5530  
5540  
5550  
5560  
5570  
5580  
5590  
5600  
5610  
5620  
5630  
5640  
5650  
5660  
5670  
5680  
5690  
5700  
5710  
5720  
5730  
5740  
5750  
5760  
5770  
5780  
5790  
5800  
5810  
5820  
5830  
5840  
5850  
5860  
5870  
5880  
5890  
5900  
5910  
5920  
5930  
5940  
5950  
5960  
5970  
5980  
5990  
6000  
6010  
6020  
6030  
6040  
6050  
6060  
6070  
6080  
6090  
6100  
6110  
6120  
6130  
6140  
6150  
6160  
6170  
6180  
6190  
6200  
6210  
6220  
6230  
6240  
6250  
6260  
6270  
6280  
6290  
6300  
6310  
6320  
6330  
6340  
6350  
6360  
6370  
6380  
6390  
6400  
6410  
6420  
6430  
6440  
6450  
6460  
6470  
6480  
6490  
6500  
6510  
6520  
6530  
6540  
6550  
6560  
6570  
6580  
6590  
6600  
6610  
6620  
6630  
6640  
6650  
6660  
6670  
6680  
6690  
6700  
6710  
6720  
6730  
6740  
6750  
6760  
6770  
6780  
6790  
6800  
6810  
6820  
6830  
6840  
6850  
6860  
6870  
6880  
6890  
6900  
6910  
6920  
6930  
6940  
6950  
6960  
6970  
6980  
6990  
7000  
7010  
7020  
7030  
7040  
7050  
7060  
7070  
7080  
7090  
7100  
7110  
7120  
7130  
7140  
7150  
7160  
7170  
7180  
7190  
7200  
7210  
7220  
7230  
7240  
7250  
7260  
7270  
7280  
7290  
7300  
7310  
7320  
7330  
7340  
7350  
7360  
7370  
7380  
7390  
7400  
7410  
7420  
7430  
7440  
7450  
7460  
7470  
7480  
7490  
7500  
7510  
7520  
7530  
7540  
7550  
7560  
7570  
7580  
7590  
7600  
7610  
7620  
7630  
7640  
7650  
7660  
7670  
7680  
7690  
7700  
7710  
7720  
7730  
7740  
7750  
7760  
7770  
7780  
7790  
7800  
7810  
7820  
7830  
7840  
7850  
7860  
7870  
7880  
7890  
7900  
7910  
7920  
7930  
7940  
7950  
7960  
7970  
7980  
7990  
8000  
8010  
8020  
8030  
8040  
8050  
8060  
8070  
8080  
8090  
8100  
8110  
8120  
8130  
8140  
8150  
8160  
8170  
8180  
8190  
8200  
8210  
8220  
8230  
8240  
8250  
8260  
8270  
8280  
8290  
8300  
8310  
8320  
8330  
8340  
8350  
8360  
8370  
8380  
8390  
8400  
8410  
8420  
8430  
8440  
8450  
8460  
8470  
8480  
8490  
8500  
8510  
8520  
8530  
8540  
8550  
8560  
8570  
8580  
8590  
8600  
8610  
8620  
8630  
8640  
8650  
8660  
8670  
8680  
8690  
8700  
8710  
8720  
8730  
8740  
8750  
8760  
8770  
8780  
8790  
8800  
8810  
8820  
8830  
8840  
8850  
8860  
8870  
8880  
8890  
8900  
8910  
8920  
8930  
8940  
8950  
8960  
8970  
8980  
8990  
9000  
9010  
9020  
9030  
9040  
9050  
9060  
9070  
9080  
9090  
9100  
9110  
9120  
9130  
9140  
9150  
9160  
9170  
9180  
9190  
9200  
9210  
9220  
9230  
9240  
9250  
9260  
9270  
9280  
9290  
9300  
9310  
9320  
9330  
9340  
9350  
9360  
9370  
9380  
9390  
9400  
9410  
9420  
9430  
9440  
9450  
9460  
9470  
9480  
9490  
9500  
9510  
9520  
9530  
9540  
9550  
9560  
9570  
9580  
9590  
9600  
9610  
9620  
9630  
9640  
9650  
9660  
9670  
9680  
9690  
9700  
9710  
9720  
9730  
9740  
9750  
9760  
9770  
9780  
9790  
9800  
9810  
9820  
9830  
9840  
9850  
9860  
9870  
9880  
9890  
9900  
9910  
9920  
9930  
9940  
9950  
9960  
9970  
9980  
9990  
10000  
10010  
10020  
10030  
10040  
10050  
10060  
10070  
10080  
10090  
10100  
10110  
10120  
10130  
10140  
10150  
10160  
10170  
10180  
10190  
10200  
10210  
10220  
10230  
10240  
10250  
10260  
10270  
10280  
10290  
10300  
10310  
10320  
10330  
10340  
10350  
10360  
10370  
10380  
10390  
10400  
10410  
10420  
10430  
10440  
10450  
10460  
10470  
10480  
10490  
10500  
10510  
10520  
10530  
10540  
10550  
10560  
10570  
10580  
10590  
10600  
10610  
10620  
10630  
10640  
10650  
10660  
10670  
10680  
10690  
10700  
10710  
10720  
10730  
10740  
10750  
10760  
10770  
10780  
10790  
10800  
10810  
10820  
10830  
10840  
10850  
10860  
10870  
10880  
10890  
10900  
10910  
10920  
10930  
10940  
10950  
10960  
10970  
10980  
10990  
11000  
11010  
11020  
11030  
11040  
11050  
11060  
11070  
11080  
11090  
11100  
11110  
11120  
11130  
11140  
11150  
11160  
11170  
11180  
11190  
11200  
11210  
11220  
11230  
11240  
11250  
11260  
11270  
11280  
11290  
11300  
11310  
11320  
11330  
11340  
11350  
11360  
11370  
11380  
11390  
11400  
11410  
11420  
11430  
11440  
11450  
11460  
11470  
11480  
11490  
11500  
11510  
11520  
11530  
11540  
11550  
11560  
11570  
11580  
11590  
11600  
11610  
11620  
11630  
11640  
11650  
11660  
11670  
11680  
11690  
11700  
11710  
11720  
11730  
11740  
11750  
11760  
11770  
11780  
11790  
11800  
11810  
11820  
11830  
11840  
11850  
11860  
11870  
11880  
11890  
11900  
11910  
11920  
11930  
11940  
11950  
11960  
11970  
11980  
11990  
12000  
12010  
12020  
12030  
12040  
12050  
12060  
12070  
12080  
12090  
12100  
12110  
12120  
12130  
12140  
12150  
12160  
12170  
12180  
12190  
12200  
12210  
12220  
12230  
12240  
12250  
12260  
12270  
12280  
12290  
12300  
12310  
12320  
12330  
12340  
12350  
12360  
12370  
12380  
12390  
12400  
12410  
12420  
12430  
12440  
12450  
12460  
12470  
12480  
12490  
12500  
12510  
12520  
12530  
12540  
12550  
12560  
12570  
12580  
12590  
12600  
12610  
12620  
12630  
12640  
12650  
12660  
12670  
12680  
12690  
12700  
12710  
12720  
12730  
12740  
12750  
12760  
12770  
12780  
12790  
12800  
12810  
12820  
12830  
12840  
12850  
12860  
12870  
12880  
12890  
12900  
12910  
12920  
12930  
12940  
12950  
12960  
12970  
12980  
12990  
13000  
13010  
13020  
13030  
13040  
13050  
13060  
13070  
13080  
13090  
13100  
13110  
13120  
13130  
13140  
13150  
13160  
13170  
13180  
13190  
13200  
13210  
13220  
13230  
13240  
13250  
13260  
13270  
13280  
13290  
13300  
13310  
13320  
13330  
13340  
13350  
13360  
13370  
13380  
13390  
13400  
13410  
13420  
13430  
13440  
13450  
13460  
13470  
13480  
13490  
13500  
13510  
13520  
13530  
13540  
13550  
13560  
13570  
13580  
13590  
13600  
13610  
13620  
13630  
13640  
13650  
13660  
13670  
13680  
13690  
13700  
13710  
13720  
13730  
13740  
13750  
13760  
13770  
13780  
13790  
13800  
13810  
13820  
13830  
13840  
13850  
13860  
13870  
13880  
13890  
13900  
13910  
13920  
13930  
13940  
13950  
13960  
13970  
13980  
13990  
14000  
14010  
14020  
14030  
14040  
14050  
14060  
14070  
14080  
14090  
14100  
14110  
14120  
14130  
14140  
14150  
14160  
14170  
14180  
14190  
14200  
14210  
14220  
14230  
14240  
14250  
14260  
14270  
14280  
14290  
14300  
14310  
14320  
14330  
14340  
14350  
14360  
14370  
14380  
14390  
14400  
14410  
14420  
14430  
14440  
14450  
14460  
14470  
14480  
14490  
14500  
14510  
14520  
14530  
14540  
14550  
14560  
14570  
14580  
14590  
14600  
14610  
14620  
14630  
14640  
14650  
14660  
14670  
14680  
14690  
14700  
14710  
14720  
14730  
14740  
14750  
14760  
14770  
14780  
14790  
14800  
14810  
14820  
14830  
14840  
14850  
14860  
14870  
14880  
14890  
14900  
14910  
14920  
14930  
14940  
14950  
14960  
14970  
14980  
14990  
15000  
15010  
15020  
15030  
15040  
15050  
15060  
15070  
15080  
15090  
15100  
15110  
15120  
15130  
15140  
15150  
15160  
15170  
15180  
15190  
15200  
15210  
15220  
15230  
15240  
15250  
15260  
15270  
15280  
15290  
15300  
15310  
15320  
15330  
15340  
15350  
15360  
15370  
15380  
15390  
15400  
15410  
15420  
15430  
15440  
15450  
15460  
15470  
15480  
15490  
15500  
15510  
15520  
15530  
15540  
15550  
15560  
15570  
15580  
15590  
15600  
15610  
15620  
15630  
15640  
15650  
15660  
15670  
15680  
15690  
15700  
15710  
15720  
15730  
15740  
15750  
15760  
15770  
15780  
15790  
15800  
15810  
15820  
15830  
15840  
15850  
15860  
15870  
15880  
15890  
15900  
15910  
15920  
15930  
15940  
15950  
15960  
15970  
15980  
15990  
16000  
16010  
16020  
16030  
16040  
16050  
16060  
16070  
16080  
16090  
16100  
16110  
16120  
16130  
16140  
16150  
16160  
16170  
16180  
16190  
16200  
16210  
16220  
16230  
16240  
16250  
16260  
16270  
16280  
16290  
16300  
16310  
16320  
16330  
16340  
16350  
16360  
16370  
16380  
16390  
16400  
16410  
16420  
16430  
16440  
16450  
16460  
16470  
16480  
16490  
16500  
16510  
16520  
16530  
16540  
16550  
16560  
16570  
16580  
16590  
16600  
16610  
16620  
16630  
16640  
16650  
16660  
16670  
16680  
16690  
16700  
16710  
16720  
16730  
16740  
16750  
16760  
16770  
16780  
16790  
16800  
16810  
16820  
16830  
16840  
16850  
16860  
16870  
16880  
16890  
16900  
16910  
16920  
16930  
16940  
16950  
16960  
16970  
16980  
16990  
17000  
17010  
17020  
17030  
17040  
17050  
17060  
17070  
17080  
17090  
17100  
17110  
17120  
17130  
17140  
17150  
17160  
17170  
17180  
17190  
17200  
17210  
17220  
17230  
17240  
17250  
17260  
17270  
17280  
17290  
17300  
17310  
17320  
17330  
17340  
17350  
17360  
17370  
17380  
17390  
17400  
17410  
17420  
17430  
17440  
17450  
17460  
17470  
17480  
17490  
17500  
17510  
17520  
17530  
17540  
17550  
17560  
17570  
17580  
17590  
17600  
17610  
17620  
17630  
17640  
17650

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE*	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## GENETIC MATERIAL ENCODING IGFBP-5

5

This application is a division of U.S. application serial number 07/574,613, filed August 28, 1990 (attorney docket number CHIR-007/00 US).

10

INTRODUCTIONField of the Invention

This invention relates to genetic engineering of naturally occurring proteins and to corresponding recombinant proteins, genes, and gene segments and more specifically to such proteins and genetic elements derived from an insulin-like growth factor-binding protein, to methods and compositions which employ the genetic elements, and to gene segments that are useful in diagnosis.

20

Background

Insulin-like growth factors (IGFs) are low molecular weight polypeptide hormones with structural homology to proinsulin. Two different IGFs are known, namely IGF-I and IGF-II, which are mitogenic in vitro for a wide variety of cells in tissue culture. Both IGFs stimulate in vitro the growth of various tissues and in particular they induce collagen synthesis. IGF-I mediates the growth promoting effect of growth hormone in chondrogenesis and bone formation and is therefore essential for normal growth of an individual. This is demonstrated by the fact that pygmies and toy poodles are deficient in IGF-I but have normal growth hormone level in their serum. IGF-II is believed to play a key role in fetal development and nerve growth.

30

35

In addition to their primary effect on skeletal tissue they also exhibit growth-stimulating functions on other tissues. Wound fibroblasts are

---

known to produce IGFs which are effective in stimulating fibroblasts to grow and synthesize collagen, a structural protein normally required for wound healing. Vascularization of the wound tissue is also induced.

5 Further, it has also been found that IGFs have an erythropoietin-like activity in that they induce hematopoiesis.

Recent studies have also demonstrated that IGFs produced by certain cancer cells, e.g. breast and  
10 kidney cancer cells, auto-stimulate the proliferation of cancer cells and the vascular and fibrous tissues required to support the growth of cancer tissues.

In addition to this, both IGFs show a spectrum of metabolic activities similar to those of  
15 insulin, in that they stimulate, in particular, the transport and metabolism of glucose. The biological effects of IGFs and insulin are mediated through their binding to specific receptors. In particular, both IGFs have the ability to bind to the insulin receptor  
20 with approximately 100-fold lower affinity than does insulin.

Both IGFs have a concentration in blood approximately a hundred-fold higher than that of insulin. Hypoglycemia is prevented by a regulatory  
25 mechanism which involves carrier proteins present in blood and able to form complexes with IGFs. Thus, IGFs circulate in the blood in the form of a complex which has no insulin-like activity. Through their association with carrier protein (hereinafter referred  
30 to as IGF-binding proteins or IGFBPs), binding of IGFs to cell surface receptors is inhibited. It has also been demonstrated that another function of the IGF-binding proteins is to increase the short half-life of IGFs, which are subjected to rapid proteolytic  
35 degradation when present in the free form in blood.

In accordance with the foregoing, IGFs may be useful in vitro to stimulate a) the growth of animals and humans with growth hormone deficiency, b) tissue

regeneration, such as erythropoiesis and chondrogenesis, c) wound healing and d) the functions of various organs e.g. liver or kidney. As a result of their chondrogenesis stimulating activity, IGFs are of particularly suitable use for bone formation, e.g. in the treatment of osteoporosis. IGFs for use in the above-referred treatments are advantageously administered to a subject in association with at least one IGF-binding protein. Administration of this combination rather than IGF alone has beneficial effects including the prevention of hypoglycemia and possible mitogenic effects at injection sites and the prolongation of IGF half-life. Further, it has been found that binding proteins are also useful for potentiating the erythropoietin like-effect of IGF-I. The binding proteins may also be useful for targeting IGFs to specific tissues.

When administered alone, i.e., without any IGF, the binding proteins may also be therapeutically useful for blocking the adverse effects of IGFs, such as those which occur when IGFs are produced in excess, e.g. free IGFs secreted by certain cancer cells e.g. hormone-producing cancer cells such as breast or kidney cancer cells. IGF-binding-protein therapy may also prevent blindness as a secondary effect of diabetic proliferation retinopathy. Indeed it has been shown that IGFs may be one of the factors stimulating endothelial and fibroblast proliferation in diabetic retinopathy.

Another therapeutic use of IGFBPs is the control of excessive growth in IGF-binding-protein-deficient subjects, since it is very likely that high IGF levels combined with abnormally low levels of binding protein are responsible for excessive growth.

In recent years, three major species of IGF-binding proteins, different in size and other properties, have been detected in the serum of rodents and humans.

---

The first binding protein discovered, now called IGFBP-3, is a glycoprotein of approximately 150 kd and composed of several subunits. Its formation, in contrast to that of the second, smaller IGF-binding protein, is growth hormone dependent.

The second binding protein discovered, now called IGFB-1, has a molecular weight of approximately 30 - 40 kd in the human and the rat. The human IGFBP-1 has already been purified from various sources including amniotic fluid (Povoa, G. et al., Eur. J. Biochem (1984) 144 : 199, (therefore also referred to as amniotic fluid binding protein), placenta (Koistinen, R. et al., Endocrinology (1986) 118 : 1375), and conditioned medium of hepatoma G2 cells (Powell, D. R. et al., J. Chromatogr. (1987) 420: 163). The first two binding proteins have been characterized by their amino acid contents and their N-terminal amino acid sequences, and found identical or at least very similar. The comparison of the amino acid sequences of the IGF-binding protein isolated from hepatoma G2 cells (Lee, Y. L. et al., Mol. Endocrinol. (1988) 2 (5): 404) and the IGF-binding protein cloned from a placenta cDNA library (Brinkman, A. et al., The EMBO Journal (1988) 7 (8) : 2417) reveals 99% homology. Further, these two amino acid sequences shown with the IGF-binding protein as coded by a cDNA library a homology of 94% (Brewer, M.T. et al., Bioch. Biophys. Res. Com. (1988) 152(3): 1289).

In addition to the two major forms of IGF-binding proteins present in serum several other IGF-binding proteins have been identified in different human tissue extracts and cell culture media by Western blotting techniques and affinity labelling with [ $I^{125}$ ]-IGF. Their molecular weights range from 15 to 150 kd and some of these proteins appear to be generated by proteolytic degradation of the larger IGF-binding-proteins. In particular, a 53 kd IGF-binding protein which has been purified from human serum represents a

subunit of the 150-kd IGFBP-1 (Baxter, R.C. Biochem Biophys. Res. Com. (1966 139(3):1256).

Another form of IGF-binding protein has also been found in the conditioned medium from rat BRL-3A cells, and has a molecular weight of 33-36 kd approximately. A partial amino-terminal protein sequence of the rat BRL-3A binding protein has been determined (Mottolla, C. et al., of Biol. Chem. (1986) 261:11180; Lyons, R.M. Smith. G.L., Mol. Cell. Endocrinol (1986) 45:263). The 33% degree of homology shown by the rat and human terminal sequences is not high enough to allow the respective binding proteins to be considered as equivalents.

An additional IGFBP, now called IGFBP-2, which is related to the BRL-3A binding protein, has also been found and its amino acid sequence fully established. The amino acid sequence of IGFBP-2 is distinct from that of the previously known binding proteins.

The existence of a number of different IGF-binding proteins indicate that these proteins have different functions. Since it is possible to diagnose disease states and to modify in various different ways the biological activity of IGFs using the currently known binding proteins, there is significant interest in the discovery of additional IGF-binding proteins having different biological properties.

#### Relevant Literature

1. Daughaday, W.H., and Rotwein, P. (1989) Endocrine Reviews 10, 68-91.
  2. Nissley, S.P., and Rechler, M.M. (1984). In: Hormonal Proteins and Peptides (C.H. Li, ed.) p. 127-203. Academic Press, New York and London.
  3. Cohen, K.L., and Nissley, S.P. (1976) Acta Endocr. (Kbh.) 83, 243-258.
  4. Zapf, J., Hauri, Ch., Waldvogel, M. and Froesch, E.R. (1986) J. Clin. Invest. 77, 1768-1775.
-

5. Guler, H.P., Zapf, J., Schmid, Ch., and Froesch, E.R. (1989) *Acta Endocr (Kbh.)* 121, 753-758.
6. Zapf, J., Hauri, C., Waldvogel, M., Futo, E., Hasler, H., Binz, K., Guler, H.P., Schmid, C., and Froesch, E.R. (1989) *Proc. Natl. Acad. Sci. USA* 86, 3813-3817.
7. Schmid, C., Zapf, J., and Froesch, E.R. (1989) *FEBS Letters* 244, 328-332.
8. Schmid, Ch, Ernst, M., Zapf, J., and Froesch, E.R. (1989) *Biochem. Biophys. Res. Commun.* 160, 788-794.
9. Elgin, R.G., Busby, W.H., and Clemmons, D.R. (1987) *Proc. Natl. Acad. Sci. USA* 84, 3254-3258.
10. De Mellow, J.S.M., and Baxter, R.C. (1988) *Biochem. Biophys. Res. Commun.* 156, 199-204.
11. Knauer, D.J., and Smith, G.L. (1980) *Proc. Nat. Acad. Sci. USA* 77, 7252-7256.
12. Zapf, J., Waldvogel, M., and Froesch, E.R. (1975) *Arch. Biochem. Biophys.* 168, 638-645.
13. Hintz, R.L., Liu, F., Rosenfeld, R.G. and Kemp, S.F. (1981) *J. Clin. Endocrinol. Metab.*, 53:100-104.
14. Martin, J.L., and Baxter, R.C. (1981) *J. Clin. Endocrinol. Metab.* 61, 799-801.
15. Baxter, R.C., and Martin, J.L. (1989) *Proc. Natl. Acad. Sci. USA* 86, 6898-6902.
16. Wood, W.I., Cachianes, G., Henzel, W.J., Winslow, G.A., Spencer, S.A., Hellmiss, R., Martin, J.L., and Baxter, R.C. (1988) *Molecular Endocrinology* 2, 1176-1185.
17. Zapf, J., Schmid, Ch., Guler, H.P., Waldvogel, M., Hauri, Ch., Futo, E., Hossenlopp, p., Binoux, M., and Froesch, E.R. 91990) *J. Clin. Invest.*; in press.
18. Martin, J.L., and Baxter, R.C. (1986) *J. Biol. Chem.* 261, 8754-8760.
19. Zapf, J., Born, W., Chang, J.-Y., James P., Froesch, E.R., and Fischer, J.A. (1988) *Biochem. Biophys. Res. Comm.* 156, 1187-1194.



20. Nilson, B.L., and Brown, L.R. (1984) Anal. Biochem. 141, 311-315.
  21. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S., and Binoux, M. (1986) Anal. Biochem. 154, 138-143.
  22. Zapf, J., Walter, H., and Froesch, E.R. (1981) J. Clin. Invest. 68, 1321-1330.
  23. Matsudaira, P. (1987) J. Biol. Chem. 262, 10035-10038.
  24. Yuen, S.W., Chui, A.H., Wilson, K.J., and Yuan, P.M. (1988) Applied Biosystems, User Bulletin No. 36, 1-17.
  25. Hunkapiller, M.W., Hewick, R.M., Dreyer, W.J., and Hood, L.E. (1983) Methods in Enzymology 91, 399-413.
  26. Friedman, M., Krull, L.G., and Cavins, J.F. (1980) J. Biol. Chem. 245, 3868-3871.
  27. Chirgwin, J.M., Przbyla, A.E., MacDonald, R.J., and Rutter, W.J. (1979) Biochemistry 18, 5294-5299.
  29. Aviv, H., and Leder, P. (1972) Proc. Natl. Acad. Sci. USA 69, 1408-1412.
  30. Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) Molecular Cloning, a Laboratory Manual (Cold Spring Harbor Lab, Cold Spring Harbor, NY).
  31. Binkert, C., Landwehr, J., Mary, J.-L., Schwander, J., and Heinrich G. (1989) EMBO Journal 8, 2497-2502.
  32. Margot, J.B., Binkert, C., Mary, J.-L., Landwehr, J., Heinrich, G., and Schwander, J. (1989) Molecular Endocrinology 3, 1053-1060.
  33. Okayama, H., and Berg, P. (1983) Mol. and Cell. Biol. 3, 280-289.
  34. Aruffo, A., and Seed, B. (1987) Proc. Natl. Acad. Sci. USA 84, 8573-8577.
  35. Pfeiffer, B.H., and Zimmerman, S.B. (1983) Nucl. Acids Res. 11, 7853-7871.
-

36. Benton, W.D., and Davis, R.W. (1977) *Science* 196, 180-???
37. Yanisch-Perron, C., Vieira, J., and Messing, J. (1985) *Gene* 33, 103-119.
- 5 38. Sanger, F., Nicklen, S., and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci USA* 74, 5463-5467.
39. Barr, P.J., Tjhayer, R.M., Laybourn, P., Najarian, R.C., Seela, F., and Tolan, D. (1986) *Biotechniques* 4, 428-432.
- 10 40. Lehrach, H., Diamond, D., Wozney, J.M., and Boedtker, H. (1977) *Biochemistry* 16, 4743-4751.
41. Thomas, P. (1980) *Proc. Natl. Acad. Sci. USA* 77, 5201-5205.
42. Feinberg, A.P., and Vogelstein, B. (1984) *Anal. Biochem.* 137, 266-267.
- 15 43. Laron, Z. (1974) *Isr. J. Med. Sci.* 10, 1247-1253.
44. Ballard, J., Baxter, R.C., Binoux, M., Clemmons, D., Drop, S., Hall, K., Hintz, R.L., Rechler, M.M., Rutanen, E., and Schwander, J.J. (1989) *Acta Endocr. (Kbh.) (Kbh.)* 121, 751-752.
- 20 45. Roghani, M., Hossenlopp, P., Lepage, P., Balland, A., and Binoux, M. (1989) *FEBS Letters* 255, 253-258.
46. Martin, J.L., Willetts, K.E., and Baxter, R.C. (1990) *J. Biol. Chem.* 265, 4124-4130.
- 25 47. Ruoslahti, E., and Pierschbacher, M.D. (1987) *Science* 238, 491-497.
48. Obara, M., Chang, M.S., and Yamada, K.M. (1988) *Cell* 53, 649-657.
- 30 49. Mottola, C., MacDonald, R.G., Brackett, J.L., Mole, J.E., Anderson, J.K., and Czech, M.P. (1986) *J. Biol. Chem.* 261, 11180-11188.
50. Brown, A.L., Chiariotti, L., Orlowski, C.C., Mehlman, T., Burgess, W.H., Ackerman, E.J., Bruni, C.B., and Rechler, M.M. (1989) *J. Biol. Chem.* 264, 5148-5154.
- 35 51. Albiston, A.L. and A.C. Herington (1990) *Biochem. Biophys. Res. Commun.* 166, 892-897.

52. Wang, J.F., Hampton, B., Mehlman, T., Burgess, W.H., and Rechler, M.M. (1988) *Biochem. Biophys. Res. Commun.* 157, 718-726.
53. Huhtala, M.L., Koistinen, R., Palomaki, P., Partanen, P., Bohn, H., and Seppala, M. (1986) *Biochem. Biophys. Res. Commun.* 141, 263-270.
54. Lee, Y.L., Hintz, R.L., James, P.M., Lee, P.D.K., Shivley, J.E., and Powell, D.R. (1988) *Molecular Endocrinology* 2, 404-411.
55. Brewer, M.T., Stetler, G.L., Squires, Ch.H., Thompson, R.C., Busby, W.H., and Clemmons, D.R. (1988) *Biochem. Biophys. Res. Commun.* 152, 1289-1297.
56. Brinkman, A., Groffen, C., Kortleve, D.J., Van Kessel, A.G., and Drop, S.L.S. (1988) *EMBO Journal* 7, 2417-2423.
57. Julkunen, M., Koistinen, R., Aalto-Setälä, M., Janne, O.A., and Kontula, K. (1988) *FEBS Letters* 236, 295-302.
58. Luthman, H., Soderling-Barros, J., Persson, B., Engberg, C., Stern, I., Lake, M., Franzen, S.-A., Israelsson, M., Radn, B., Lindgren, B., Hjelmqvist, L., Enerbäck, S., Carlsson, P., Bjursell, G., Póvoa, G., Hall, K., and Jönvall, H. (1989) *Eur. J. Biochem.* 180, 259-265.
59. Mohan, S., Bautista, C.M., Wergedal, J., and Baylink, D.J., (1989) *Proc. Natl. Acad. Sci. USA* 86, 8338-8342.
60. Szabo, L., Mottershead, D.G., Ballard, F.J., and Wallace, J.C. (1988) *Biochem. Biophys. Res. Commun.* 151, 207-214.

#### SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide means for producing an IGF-binding protein by genetic engineering techniques, the binding protein having biological properties different from those of IGFBP-1, IGFBP-2, and IGFBP-3.

It is further an object of the present invention to provide recombinant DNA molecules capable of expressing the new IGF-binding protein in order that the binding protein will be more readily available.

These and other objects of the invention have been accomplished by providing genetic information encoding a binding protein selected from a group consisting of an insulin-like growth factor binding protein having an amino acid sequence which is at least 85% homologous to the amino acid sequence of Figure 1 and fragments thereof comprising at least ten (10) consecutive amino acids of said sequence, wherein said purified binding protein is capable of binding to an antibody specific for said protein or to an insulin-like growth factor. Recombinant DNA molecules comprising a nucleic acid sequence encoding the new insulin-like growth factor binding protein and its fragments are also a part of the present invention along with recombinant microorganisms and cell lines capable of expressing the protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram showing the amino acid and nucleotide sequences of a clone encoding human IGFBP-5.

Figure 2 is a schematic diagram comparing the amino acid sequences of a human binding protein of the invention, human IGFBP-5, to the known sequences of the three human binding proteins discussed above and to IGFBP-4, another newly discovered IGF-binding protein.

Areas of homology can be seen in these sequences. These areas of homology are of particular interest as they indicated areas from which DNA probes can be obtained that have a high probability of success in finding related molecules. Two such homologous areas are indicated by brackets, although other areas of homology are also present.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS

Novel compositions comprising generic sequences encoding IGFBP-5 and fragments derived therefrom are provided, together with recombinant proteins produced using the genomic sequences, and methods of using these compositions. The IGFBP-5 cDNA was initially isolated from a human osteosarcoma/ $\lambda$ ZAP cDNA library using a two-step procedure. First, small fragments of the cDNAs encoding amino acids 1 to 15 of BP5 were amplified from osteosarcoma cDNA by the polymerase chain reaction, gel purified, and sequenced. Second, perfect match-oligonucleotides were synthesized, based on the BP5 nucleotide sequence between the PCR primers, and were used as probes to isolate cDNA clones. BP5 cDNA clones showing the largest DNA insert size by agarose gel electrophoresis were sequenced. The nucleotide and encoded amino acid sequences of BP5 are shown in Figure 1.

Standard abbreviations for nucleotides and amino acids are used in these figures and elsewhere in this specification.

A number of terms used in the art of genetic engineering and protein chemistry are used herein with the following defined meanings.

Two nucleic acid fragments are "homologous" if they are capable of hybridizing to one another under hybridization conditions described in Maniatis *et al.*, *op. cit.*, pp. 320-323. However, by using the following wash conditions -- 2 x SCC, 0.1% SDS, room temperature - twice, 30 minutes each; then 2 x SCC, 0.1% SDS, 50°C -

once, 30 minutes; then 2 x SCC, room temperature twice,  
10 minutes each -- homologous sequences can be  
identified that contain at most about 25-30% basepair  
mismatches. More preferably, homologous nucleic acid  
5 strands contain 15-25% basepair mismatches, even more  
preferably 5-15% basepair mismatches. These degrees of  
homology can be selected by using more stringent wash  
conditions for identification of clones from gene  
libraries (or other sources of genetic material), as is  
10 well known in the art.

A DNA fragment is "derived from" an IGFBP-5-  
encoding DNA sequence if it has the same or substan-  
tially the same basepair sequence as a region of the  
coding sequence for the entire IGFBP-5 molecule.

15 Substantially the same means, when referring  
to biological activities, that the activities are of  
the same type although they may differ in degree. When  
referring to amino acid sequences, substantially the  
same means that the molecules in question have similar  
20 biological properties and preferably have at least 85%  
homology in amino acid sequences. More preferably, the  
amino acid sequences are at least 90% identical. In  
other uses, substantially the same has its ordinary  
English language meaning.

25 A protein is "derived from" an IGFBP-5  
molecule if it has the same or substantially the same  
amino acid sequence as a region of the IGFBP-5  
molecule.

IGFBP-5, both glycosylated and  
30 unglycosylated, or polypeptide derivatives thereof, may  
be used for producing antibodies, either monoclonal or  
polyclonal, specific to IGFBP-5. By polypeptide  
derivatives of these IGFBPs is meant polypeptides  
differing in length from natural IGFBP-5 and containing  
35 five or more amino acids from IGFBP-5 in the same  
primary order as found in IGFBP-5 as obtained from a  
natural source. Polypeptide molecules having  
substantially the same amino acid sequence as IGFBP-5

but possessing minor amino acid substitutions that do not substantially affect the ability of the IGFBP-5 polypeptide derivatives to interact with IGFBP-5-specific molecules, such as antibodies and IGF molecules, particularly IGF-I and especially IGF-II, are within the definition of IGFBP-5. Derivatives include glycosylated forms, aggregative conjugates with other IGF-BPs molecules, and covalent conjugates with unrelated chemical moieties. Covalent derivatives are prepared by linkage of functionalities to groups which are found in the IGF-BPs amino acid chain or at the N- or C-terminal residue by means known in the art.

Experiments with N-glycanase suggest that IGFBP-5 is glycosylated. Treatment of IGFBP-5 with N-glycanase shows a shift in molecular weight from 30 kD to 24 kD for IGFBP-5, strong suggesting that this binding protein is glycosylated. This is consistent with the encoded sequence.

IGFBP-5-specific molecules include polypeptides such as antibodies that are specific for the IGFBP-5 polypeptide containing the naturally occurring IGFBP-5 amino acid sequence. By "specific binding polypeptide" is intended polypeptides that bind with IGFBP-5 and its derivatives and which have a measurably higher binding affinity for the target polypeptide, i.e., IGFBP-5 and polypeptide derivatives of IGFBP-5, than for other polypeptides tested for binding. Higher affinity by a factor of 10 is preferred, more preferably a factor of 100. Binding affinity for antibodies refers to a single binding event (i.e., monovalent binding of an antibody molecule). Specific binding by antibodies also means that binding takes place at the normal binding site of the molecule's antibody (at the end of the arms in the variable region).

As discussed above, minor amino acid variations from the natural amino acid sequence of IGFBP-5 are contemplated as being encompassed by the terms IGFBP-5; in particular, conservative amino acid

---

replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided

5 into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and

10 (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with

15 a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding properties of the resulting molecule, especially if the replacement does not involve an amino acid at a binding

20 site involved in the interaction of IGFBP-5 or its derivatives with an IGF molecule. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific binding properties of the IGFBP-5 polypeptide derivative. A binding assay

25 is described in detail below.

Antibodies specific for IGFBP-5 are produced by immunizing an appropriate vertebrate host, e.g., rabbit, with purified IGFBP-5 or polypeptide derivatives of IGFBP-5, by themselves or in conjunction with a

30 conventional adjuvant. Usually, two or more immunizations will be involved, and blood or spleen will be harvested a few days after the last injection. For polyclonal antisera, the immunoglobulins can be precipitated, isolated and purified by a variety of

35 standard techniques, including affinity purification using IGFBP-5 attached to a solid surface, such as a gel or beads in an affinity column. For monoclonal antibodies, the splenocytes normally will be fused with



an immortalized lymphocyte, e.g., a myeloid cell line, under selective conditions for hybridoma formation. The hybridomas can then be cloned under limiting dilution conditions and their supernatants screened for antibodies having the desired specificity. Techniques for producing antibodies are well known in the literature and are exemplified by the publication Antibodies: A Laboratory Manual (1988) eds. Harlow and Lane, Cold Spring Harbor Laboratories Press, and U.S. Patent Nos. 4,381,292, 4,451,570, and 4,618,577.

IGFBP-5 can be readily purified from blood and its components, such as serum and plasma and from cells genetically modified to produce IGFBP-5 or polypeptide derivatives thereof, by affinity chromatography using a monoclonal antibody specific for IGFBP-5. In addition to the use of antibody affinity chromatography, IGFBP-5 and polypeptide derivatives thereof can be purified by a variety of other widely known protein purification techniques (either alone or in combination) including immunoprecipitation, gel filtration, ion exchange chromatography, chromatofocusing, isoelectric focusing, selective precipitation, electrophoresis, and the like. Fractions isolated during purification procedures can be analyzed for the presence of IGFBP-5 or polypeptide derivatives of IGFBP-5 by immunoassays employing IGFBP-5-specific antibodies or IGFBP-5-specific bioassays. Detailed examples are provided below.

Isolation of nucleotide sequences encoding IGFBP-5 involves creation of either a genomic library prepared from cells encoding IGFBP-5 or preparation of a cDNA library from RNA isolated from cells expressing IGFBP-5. It will generally be preferable to create a cDNA library for isolation of IGFBP-5-coding nucleotide sequences so as to avoid any possible problems arising from attempts to determine intron/exon borders. Genetic libraries can be made in either eukaryotic or prokaryotic host cells. Widely available cloning

---

vectors such as plasmids, cosmids, phage, YACs and the like can be used to generate genetic libraries suitable for the isolation of nucleotide sequences encoding IGFBP-5 or portions thereof.

5            Useful methods for screening genetic libraries for the presence of IGFBP-5 nucleotide sequences include the preparation of oligonucleotide probes based on the N-terminus amino acid sequence information from purified IGFBP-5 or purified internal  
10 fragments of purified IGFBP-5. By employing the standard triplet genetic code, oligonucleotide sequences of about 17 base pairs or longer can be prepared by conventional in vitro synthesis techniques so as to correspond to portions of IGFBP-5 for which  
15 the amino acid sequence has been determined by N-terminus analysis. The resultant nucleic acid sequences can be subsequently labeled with radio-nuclides, enzymes, biotin, fluorescers, or the like, and used as probes for screening genetic libraries.

20            Additional methods of interest for isolating IGFBP-5-encoding nucleic acid sequences include screening genetic libraries for the expression of IGFBP-5 or fragments thereof by means of IGFBP-5 specific antibodies, either polyclonal or monoclonal.  
25 A particularly preferred technique involves the use of degenerate primers based on partial amino acid sequences of purified IGFBP-5 or on sequences from known related molecules and the polymerase chain reaction (PCR) to amplify gene segments between the  
30 primers. The gene can then be isolated using a specific hybridization probe based on the amplified gene segment, which is then analyzed for appropriate expression of protein. A detailed description of this preferred technique is set forth in the examples that  
35 follow.

Nucleotide sequences encoding IGFBP-5 can be obtained from recombinant DNA molecules recovered from IGFBP-5 genetic library isolates. The nucleotide

sequence encoding IGFBP-5 can be obtained by sequencing the non-vector nucleotide sequences of these recombinant molecules. Nucleotide sequence information can be obtained by employing widely used DNA sequencing protocols, such as Maxim and Gilbert sequencing, dideoxy nucleotide sequencing, and the like. Examples of suitable nucleotide sequencing protocols can be found in Berger and Kimmel, Methods in Enzymology Vol. 52, Guide to Molecular Cloning Techniques, (1987) Academic Press. Nucleotide sequence information from several recombinant DNA isolates, including isolates from both cDNA and genomic libraries, may be combined so as to provide the entire amino acid coding sequence of IGFBP-5, as well as the nucleotide sequences of introns within the IGFBP-5 genes, upstream nucleotide sequences, and downstream nucleotide sequences.

Nucleotide sequences obtained from sequencing IGFBP-5 specific genetic library isolates are subjected to analysis in order to identify regions of interest in the IGFBP-5 genes. These regions of interest include open reading frames, introns, promoter sequences, termination sequences, and the like. Analysis of nucleotide sequence information is preferably performed by computer. Software suitable for analyzing nucleotide sequences for regions of interest is commercially available and includes, for example, DNASIS™ (LKB). It is also of interest to use amino acid sequence information obtained from the N-terminus sequencing of purified IGFBP-5 when analyzing IGFBP-5 nucleotide sequence information so as to improve the accuracy of the nucleotide sequence analysis.

Isolated nucleotide sequences encoding IGFBP-5 can be used to produce purified IGFBP-5 or fragments thereof by either recombinant DNA methodology or by in vitro polypeptide synthesis techniques. By "purified" and "isolated" is meant, when referring to a polypeptide or nucleotide sequence, that the indicated molecule is present in the substantial absence of other

---

biological macromolecules of the same type. The term "purified" as used herein preferably means at least 95% by weight, more preferably at least 99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000, can be present).

A significant advantage of producing IGFBP-5 by recombinant DNA techniques rather than by isolating IGFBP-5 from natural sources is that equivalent quantities of IGFBP-5 can be produced by using less starting material than would be required for isolating the binding protein from a natural source. Producing IGFBP-5 by recombinant techniques also permits IGFBP-5 to be isolated in the absence of some molecules normally present in cells that naturally produce IGFBP-5. Indeed, IGFBP compositions entirely free of any trace of human protein contaminants can readily be produced since the only human protein produced by the recombinant non-human host is the recombinant IGFBP. Potential viral agents from natural sources are also avoided. It is also apparent that recombinant DNA techniques can be used to produce IGFBP-5 polypeptide derivatives that are not found in nature, such as the variations described above.

IGFBP-5 and polypeptide derivatives of IGFBP-5 can be expressed by recombinant techniques when a DNA sequence encoding the relevant molecule is functionally inserted into a vector. By "functionally inserted" is meant in proper reading frame and orientation, as is well understood by those skilled in the art. When producing a genetic construction containing a complete IGFBP-5 reading frame, the preferred starting material is a cDNA library isolate encoding IGFBP-5 rather than a genomic library isolate. Typically, the IGFBP-5 gene will be inserted downstream from a promoter and will be followed by a stop codon, although

production as a hybrid protein followed by cleavage may be used, if desired. In general, host-cell-specific sequences improving the production yield of IGFBP-5 and IGFBP-5 polypeptide derivatives will be used and appropriate control sequences will be added to the expression vector, such as enhancer sequences, polyadenylation sequences, and ribosome binding sites.

Once the appropriate coding sequence is isolated, it can be expressed in a variety of different expression systems.

#### Mammalian Expression Systems

A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, typically located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In Molecular Cloning: A Laboratory Manual, 2nd ed.].

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition,

---

sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will typically increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they typically have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al. (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-

terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In Transcription and splicing (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In Molecular Cloning: A Laboratory Manual].

Some genes may be expressed more efficiently when introns (also called intervening sequences) are present. Several cDNAs, however, have been efficiently expressed from vectors that lack splicing

---

signals (also called splice donor and acceptor sites)  
[see e.g., Gothing and Sambrook (1981) Nature 293:620].

Introns are intervening noncoding sequences within a  
coding sequence that contain splice donor and acceptor

sites. They are removed by a process called

"splicing," following polyadenylation of the primary  
transcript [Nevins (1983) Annu. Rev. Biochem. 52:441;

Green (1986) Annu. Rev. Genet. 20:671; Padgett et al.

(1986) Annu. Rev. Biochem. 55:1119; Krainer and

Maniatis (1988) "RNA splicing." In Transcription and  
splicing (ed. B.D. Hames and D.M. Glover)].

Typically, the above described components,

comprising a promoter, polyadenylation signal, and  
transcription termination sequence are put together

into expression constructs. Enhancers, introns with  
functional splice donor and acceptor sites, and leader

sequences may also be included in an expression

construct, if desired. Expression constructs are often

maintained in a replicon, such as an extrachromosomal

element (e.g., plasmids) capable of stable maintenance

in a host, such as mammalian cells or bacteria.

Mammalian replication systems include those derived from

animal viruses, which require trans-acting factors to

replicate. For example, plasmids containing the

replication systems of papovaviruses, such as SV40

[Gluzman (1981) Cell 23:175] or polyomavirus, replicate

to extremely high copy number in the presence of the

appropriate viral T antigen. Additional examples of

mammalian replicons include those derived from bovine

papillomavirus and Epstein-Barr virus. Additionally,

the replicon may have two replication systems, thus

allowing it to be maintained, for example, in mammalian

cells for expression and in a procaryotic host for

cloning and amplification. Examples of such mammalian-

bacteria shuttle vectors include pMT2 [Kaufman et al.

(1989) Mol. Cell. Biol. 9:946 and pHEBO [Shimizu et al.

(1986) Mol. Cell. Biol. 6:1074].



Baculovirus Expression Systems

A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. A baculovirus promoter may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

Sequences encoding genes abundantly transcribed at late times in the infection cycle provide particularly useful promoter sequences. Examples include sequences derived from the polyhedrin [Friesen et al. (1986) "The Regulation of Baculovirus Gene Expression," in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); E.P.O. Pub. Nos. 127,839 and 155,476] and p10 [Vlak et al. (1988) J. Gen. Virol. 69:765] genes.

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which the case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Fusion proteins provide an alternative to direct expression. Typically, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the N-terminus of the

---

polyhedrin gene may be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., Luckow et al. (1988) Bio/technology 6:47.

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene [Carbonell et al. (1988) Gene 73:409]. Alternatively, leaders of non-baculovirus origin, such as those derived from genes encoding human alpha-interferon [Maeda et al. (1985) Nature 315:592], human gastrin-releasing peptide [Lebacqz-Verheyden et al. (1988) Molec. Cell. Biol. 8:3129], human IL-2 [Smith et al. (1985) Proc. Natl. Acad. Sci. USA 82:8404], mouse IL-3 [Miyajima et al. (1987) Gene 58:273], and human glucocerebrosidase [Martin et al. (1988) DNA 7:99] also provide for secretion in insects.

Typically, transcription termination sequences recognized by insects are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples include transcription termination sequences derived from the polyhedrin gene [Miller et al. (1988) Ann. Rev. Microbiol. 42:177].

Prior to insertion of the foreign gene into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding

sequence of interest, and transcription termination sequence, are typically put together into an intermediate transplacement construct. Intermediate transplacement constructions are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a prokaryotic host for cloning and amplification. The promoter and transcription termination sequence of the construct will typically comprise a 2.5kb section of the baculovirus genome for integration of the foreign gene into the baculovirus genome by double crossover recombination events, producing a baculovirus expression vector [Miller et al. (1989) Bloessays 4:91]. The baculovirus expression vector is typically packaged into an infectious recombinant baculovirus.

When using baculovirus expression vectors, selectable markers are, such as antibiotic resistance genes, are generally not used. Selection is typically by visual inspection for occlusion bodies. Examples are given elsewhere in this specification of the use of selectable markers.

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for inter alia: *Aedes aegypti*, *Autographa californica*, *Bombyx mori*, *Drosophila melanogaster*, *Heliothis zea*, *Spodoptera frugiperda*, and *Trichoplusia ni* [P.C.T. WO 89/046699; Carbonell et al. (1985) J. Virol. 56:153; Smith et al. (1983) Mol. Cell. Biol. 3:2156; Wright (1986) Nature 321:718; See generally, Fraser et al. (1989) In Vitro Cell. Dev. Biol. 25:225].

Methods of introducing exogenous DNA into insect hosts are well-known in the art, and typically include either the transfection of host insect cells with DNA or the infection of insect cells or live

---

insects, usually larvae, with virus. Transfection procedures are based on the calcium phosphate procedure originally developed for mammalian cells [Graham et al. (1973) *Virology* 52:456]. DNA transfection and viral infection procedures usually vary with the insect genus to be transformed. See e.g. *Autograph* [Carstens et al. (1980) *Virology* 101:311], *Heliothis (virescens)* [P.C.T. Pub. No. WO88/02030], *Spodoptera* [Kang (1988) "Baculovirus Vectors for Expression of Foreign Genes," in: Advances in Virus Research, vol. 35].

#### Bacterial Expression Systems

A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3") transcription of a coding sequence (e.g., structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) [Raibaud et al. (1984) *Annu. Rev. Genet.* 18:173]. Regulated expression may therefore be either positive or

negative, thereby either enhancing or reducing transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences.

5 Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp)  
10 [Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. Patent No. 4,738,921; E.P.O. Pub. Nos. 36,776 and 121,775]. The  $\gamma$ -lactamase (bla) promoter system [Weissmann (1981) "The cloning of interferon and other  
15 mistakes." In Interferon 3 (ed. I. Gresser)], bacteriophage lambda PL [Shimatake et al. (1981) Nature 292:128] and T5 [U.S. Patent No. 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not  
20 occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid  
25 promoter [U.S. Patent No. 4,551,433]. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci.  
30 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled  
35 with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al.

---

(1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074]. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (E.P.O. Pub. No. 267,851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In E. coli, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine et al. (1975) Nature 254:34]. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of E. coli 16S rRNA [Steitz et al. (1979) "Genetic signals and nucleotide sequences in messenger RNA." In Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site [Sambrook et al. (1989) "Expression of cloned genes in *Escherichia coli*." In Molecular Cloning: A Laboratory Manual].

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo or in vitro incubation with a bacterial methionine N-terminal peptidase (E.P.O. Pub. No. 219,237).

Fusion proteins provide an alternative to direct expression. Typically, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino

acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al. (1987) Gene 60:197], trpE [Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11], and Chey [E.P.O. Pub. No. 324,647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated [Miller et al. (1989) Bio/Technology 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Patent No. 4,336,336]. The signal sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA)

---

[Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; E.P.O. Pub. No. 244,042].

Typically, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.

Typically, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and typically about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and



more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

5           Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors typically contain at least one sequence homologous to the bacterial chromosome that allows the vector to  
10   integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (E.P.O. Pub. No. 127,328). Integrating vectors may also be  
15   comprised of bacteriophage or transposon sequences.

Typically, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have  
20   been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol.  
25   32:469]. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation  
30   vectors. Transformation vectors are typically comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either  
35   extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: *Bacillus subtilis*

---

[Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; E.P.O. Pub. Nos. 36,259 and 63,953; P.C.T. WO 84/04541], *Escherichia coli* [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. 5 (1986) J. Mol. Biol. 189:113; E.P.O. Pub. Nos. 36,776, 136,829 and 136,907; U.K. Patent Application Serial No. 8418273], *Streptococcus cremoris* [Powell et al. (1988) Appl. Environ. Microbiol. 54:655]; *Streptococcus lividans* [Powell et al. (1988) Appl. Environ. Microbiol. 10 54:655], *Streptomyces lividans* [U.S. Patent No. 4,745,056].

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and typically include either the transformation of bacteria 15 treated with  $\text{CaCl}_2$  or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See e.g., [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; E.P.O. Pub. Nos. 36,259 and 20 63,953; P.C.T. WO 84/04541, *Bacillus*], [Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, *Campylobacter*], [Cohen et al. 25 (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of *Escherichia coli* with ColE1-derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. 30 (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318; *Escherichia*], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 *Lactobacillus*]; [Fiedler et al. (1988) Anal. Biochem 170:38, 35 *Pseudomonas*]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, *Staphylococcus*], [Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of *Streptococcus lactis* by electroporation, in:

Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infec. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, Streptococcus].

#### Description: Yeast Expression System

A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH)(E.P.O. Pub. No. 284044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK)(E.P.O. Pub. No. 329203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For

---

example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK(E.P.O. Pub. No. 164556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes i the Yeast *Saccharomyces cerevisiae*," in: Plasmids of Medical, Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Fusion proteins provide an alternative to direct expression. Typically, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this

construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., E.P.O. Pub. No. 196056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (P.C.T. WO 88/024066; commonly owned U.S. Patent Application Serial No. 359,599, filed 7 August 1989, the disclosure of which is incorporated herein by reference). This system is the currently preferred system for producing IGFBP-5.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (E.P.O. Pub. No. 12873; J.P.O. Pub. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (E.P.O. Pub. No. 60057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor

---

gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (typically about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; E.P.O. Pub. No. 324274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (See e.g., P.C.T. WO 89/02463.)

Typically, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Typically, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein et al. (1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982) J. Mol. Biol. 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid

will generally have a copy number ranging from about 5 to about 200, and typically about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake et al., supra.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors typically contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver et al., supra. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Typically, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast

---

cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of

5 CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol. Rev. 51:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are typically

10 comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have

15 been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: *Candida albicans* [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], *Candida maltosa* [Kunze, et al. 1985) J. Basic Microbiol.

20 25:141]. *Hansenula polymorpha* [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], *Kluyveromyces fragilis* [Das, et al. (1984) J. Bacteriol. 158:1165], *Kluyveromyces lactis* [De Louvencourt et al. (1983) J. Bacteriol.

25 154:737; Van den Berg et al. (1990) Bio/Technology 8:135], *Pichia guilliermondii* [Kunze et al. (1985) J. Basic Microbiol. 25:141], *Pichia pastoris* [Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555], *Saccharomyces cerevisiae*

30 [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163], *Schizosaccharomyces pombe* [Beach and Nurse (1981) Nature 300:706], and *Yarrowia lipolytica* [Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al.

35 (1985) Curr. Genet. 10:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and typically include either the transformation of spheroplasts or of



intact yeast cells treated with alkali cations.

Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz et al.

(1986) Mol. Cell. Biol. 6:142; Kunze et al. 91985) J.

5 Basic Microbiol. 25:141; *Candida*]; [Gleeson et al.

91986) J. Gen. Microbiol. 132:3459; Roggenkamp et al.

(1986) Mol. Gen. Genet. 202:302; *Hansenula*]; [Das et

al. (1984) J. Bacteriol. 158:1165; De Louvencourt et

al. (1983) J. Bacteriol. 154:1165; Van den Berg et al.

10 (1990) Bio/Technology 8:135; *Kluyveromyces*]; [Cregg et

al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985)

J. Basic Microbiol. 25:141; U.S. Patent Nos. 4,837,148

and 4,929,555; *Pichia*]; [Hinnen et al. (1978) Proc.

Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J.

15 Bacteriol. 153:163 *Saccharomyces*]; [Beach and Nurse

(1981) Nature 300:706; *Schizosaccharomyces*]; [Davidow et

al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985)

Curr. Genet. 10:49; *Yarrowia*].

## 20 Diagnostic Methods using Antigens

The compositions comprising antigens of the invention, as well as the genetic material, can be used in diagnostic assays. Among the biologically useful information that can be obtained is excessive binding

25 protein levels due to the presence of tumors, that result in increased production of either IGF or one of the IGFBP binding proteins (since the binding proteins are produced in the presence of excess IGF).

Additionally, a number of known disorders can be

30 related to IGF concentrations. For example, some types of osteoporosis is related to IGF levels.

Additionally, the binding proteins can be used in the identification, production, and purification of recombinantly produced IGFs. Methods for detecting the

35 presence of IGFBP-5 comprise analyzing a biological sample such as a blood sample, cerebrospinal fluid, or tumor or bone tissue.

---

Typically, methods for detecting analytes such as binding proteins of the invention are based on immunoassays. Such techniques are well known and need not be described here in detail. Examples include both heterogeneous and homogeneous immunoassay techniques. Both techniques are based on the formation of an immunological complex between the binding protein and a corresponding specific antibody. Heterogeneous assays for IGFBP-5 typically use a specific monoclonal or polyclonal antibody bound to a solid surface. Sandwich assays are increasingly popular. Homogeneous assays, which are carried out in solution without the presence of a solid phase, can also be used, for example by determining the difference in enzyme activity brought on by binding of free antibody to an enzyme-antigen conjugate. A number of suitable assays are disclosed in U.S. Patent Nos. 3,817,837, 4,006,360, 3,996,345.

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activate carboxyl, hydroxyl, or aldehyde group.

In a second diagnostic configuration, known as a homogeneous assay, antibody binding to an analyte produces some change in the reaction medium which can be directly detected in the medium. Known general types of homogeneous assays proposed heretofore include (a) spin-labeled reporters, where antibody binding to the antigen is detected by a change in reported mobility (broadening of the spin splitting peaks), (b) fluorescent reporters, where binding is detected by a change in fluorescence efficiency, (c) enzyme reporters, where antibody binding effects enzyme/substrate interactions, and (d) liposome-bound reporters, where

binding leads to liposome lysis and release of encapsulated reporter. The adaptation of these methods to the protein antigen of the present invention follows conventional methods for preparing homogeneous assay reagents.

#### Diagnostic Applications using Genetic Probes

The genetic material of the invention can itself be used in numerous assays as probes for genetic material present in naturally occurring materials. The analyte can be a nucleotide sequence which hybridizes with a probe comprising a sequence of (usually) at least about 16 consecutive nucleotides, usually 30 to 200 nucleotides, up to substantially the full sequence of the sequences shown above (cDNA sequences). The analyte can be RNA or cDNA. The sample is typically as described in the previous section. A positive result is generally characterized as identifying a genetic material comprising a sequence at least about 70% homologous to a sequence of at least 12 consecutive nucleotides of the sequences given herein, usually at least about 80% homologous to at least about 60 consecutive nucleotides within the sequences, and may comprise a sequence substantially homologous to the full-length sequences. In order to detect an analyte, where the analyte hybridizes to a probe, the probe may contain a detectable label. Probes that are particularly useful for detecting binding proteins are based on conserved regions of these proteins, particularly from amino acids PNCD and amino acids CWCV of BP5 as shown in brackets in Figure 1. These amino acids are highly conserved in all of the related IGF binding proteins. Only IGFBP-1 has a difference, a V for a D at position 191.

One method for amplification of target nucleic acids, for later analysis by hybridization assays, is known as the polymerase chain reaction or PCR technique. The PCR technique can be applied to

---

detecting IGFBP-5 of the invention in suspected samples using oligonucleotide primers spaced apart from each other and based on the genetic sequence set forth herein. The primers are complementary to opposite  
5 strands of a double stranded DNA molecule and are typically separated by from about 50 to 450 nt or more (usually not more than 2000 nt). This method entails preparing the specific oligonucleotide primers and then repeated cycles of target DNA denaturation, primer  
10 binding, and extension with a DNA polymerase to obtain DNA fragments of the expected length based on the primer spacing. Extension products generated from one primer serve as additional target sequences for the other primer. The degree of amplification of a target sequence  
15 is controlled by the number of cycles that are performed and is theoretically calculated by the simple formula  $2^n$  where n is the number of cycles. Given that the average efficiency per cycle ranges from about 65% to 85%, 25 cycles produce from 0.3 to 4.8 million copies of the  
20 target sequence. The PCR method is described in a number of publications, including Saiki *et al.*, Science (1985) 230:1350-1354; Saiki *et al.*, Nature (1986) 324:163-166; and Scharf *et al.*, Science (1986) 233:1076-1078. Also see U.S. Patent Nos. 4,683,194; 4,683,195; and  
25 4,683,202.

The invention includes a specific diagnostic method for determination of IGFBP-5, based on selective amplification of IGFBP-5-encoding DNA fragments. This method employs a pair of single-strand primers derived  
30 from non-homologous regions of opposite strands of a DNA duplex fragment selected from the sequences set forth in Figure 1. These "primer fragments," which form one aspect of the invention, are prepared from IGFBP-5 fragments such as described above. The method follows  
35 the process for amplifying selected nucleic acid sequences as disclosed in U.S. Patent No. 4,683,202, as discussed above.

### Monoclonal Antibodies

For both in vivo use of antibodies to IGFBP-5 and anti-idiotypic antibodies and diagnostic use, it may be preferable to use monoclonal antibodies. Monoclonal anti-virus particle antibodies or anti-idiotypic antibodies can be produced as follows. The spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art. To produce a human-human hybridoma, a human lymphocyte donor is selected. Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary in vitro immunization with peptides can also be used in the generation of human monoclonal antibodies. Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity.

### Assay for Biological Properties of IGFBP-5

The property of binding to an insulin-like growth factor is one of the biological activities of the proteins of the invention. These proteins may be conveniently tested in a binding assay using IGF-I [Rinderknecht, E. and Humbel, R.E., J. Biol. Chem. (1978) 253: 2769] or IGF-II [Rinderknecht, E. and Humbel, R.E., FEBS (1978) 89: 283], preferably IGF-II, in a labelled, e.g., iodinated form. For example, such an assay may conveniently include performing a gel electrophoresis (SDS-PAGE) of the proteins of the invention, followed by a western blot of the gel, then incubating the blot in the presence of [<sup>125</sup>I]IGF-I or II, washing the blot to remove free IGF-I or -II, and detecting the radioactivity on the blot.

### Sources of IGFBP-5

While IGF-BPs of the invention originally means human IGF-BPs, IGF-BPs of mammals, e.g., murine,

---

procine, equine or bovine, are included within the definition of IGF-BPs as long as they comply with the required degree of homology.

5 The IGF-BPs of the invention include those purified from a tissue extract or from a conditioned culture medium as well as those obtained by recombinant means.

#### Uses of IGFBP-5

10 Therapeutic applications of the binding proteins of the invention include its use as a single therapeutic agent and its use in combination with an IGF, the latter use being preferred.

15 When used in combination with an IGF, a binding protein of the invention is suitable for use in the indications above mentioned, primarily as a growth inducing, tissue regenerating or wound healing agent.

Accordingly, the invention provides:

20 i) use of a binding protein of the invention together with IGF in free or fixed combination for stimulating the growth of a subject, tissue or organ regeneration or wound healing, or

25 ii) a method of stimulating the growth of a subject, tissue or organ regeneration or wound healing in a subject which comprises administering a therapeutically effective amount of a binding protein of the invention together with a therapeutically effective amount of an IGF to a patient in need of such treatment, or

30 iii) a pharmaceutical composition for stimulating the growth of a subject, tissue or organ regeneration or wound healing which comprises a binding protein of a invention together with an IGF and with a pharmaceutically acceptable carrier or diluent, or

35 iv) a package containing separate until dose forms of a binding protein of the invention and an IGF, together with instructions for mixing or concomitant administration.

In association with an IGF, a binding protein of the invention is of special interest for mediating chondrogenesis or hematopoieses. This may be shown in the following tests A to C.

5           A) An IGF increases bone formation as indicated by e.g. an increased incorporation of [3H]-proline into collagen and non-collagen proteins in fetal rat calvaria. A synergistic effect occurs when an IGF is used in the presence of a binding protein of  
10 the invention. Organ cultures of rat calvaria are prepared by dissecting frontal and parietal bones from 21-day old fetal rats, splitting along the sagittal suture and culturing according to the method of Kream et al. (Endocrinology (1985) 116:296). A binding  
15 protein or IGF is added in doses from 10 to 200 ng ml of cultures. When they are added to combination to each other the molar ratio is 1:1. Culturing is effected for 24 to 48 hours. To quantitate the incorporation of [3H]proline into collagenase-  
20 digestible protein and non-collagen protein, bone homogenates are digested with bacterial collagenase according to the method of Diegelman R. and Peterkofsky (Dev. Biol. (1972) 28:443) and modified by Kream et al. (Endocrinology (1985) 116:296).

25           B) An IGF decreases bone resorption as indicated by a decrease in release of [45]Ca from bone. A synergistic effect occurs when an IGF is used in the presence of a binding protein of the invention. The  
30 test is effected according to the principles of Raisz (J. Clin. Invest. (1965) 44:103). Pregnant rats are injected s.c. with [45]Ca on the eighteenth day of gestation. An IGF, alone or in the presence of a binding protein of the invention, is injected at a dose of 10 ng to 200 ng per animal. The binding protein is  
35 added so that the molar ratio of IGF is 1:1. On day nineteen, the animals are sacrificed, the fetuses removed. The mineralized shafts of the radii and ulnae are dissected and placed in culture. Resorption is

---

quantitated on the basis of release of [45]Ca from the bone explants.

C) The IGF-binding proteins of the invention as well as other IGF-binding proteins potentiate the erythropoietin-like effect of IGF-I. This may be, in particular, demonstrated by testing IGF-I, e.g. 10 ng/ml IGF-I, alone and in combination with the mature IGF binding protein of Figure 1, e.g. a 50  $\mu$ l aliquot of a supernatant derived from a culture of a CHO cell line expressing the mature IGF binding protein of Figure 1, in a CFU-E assay as described in Fagg, B. Roitsch, C.A. Cell, Physiol. (1986) 126:1. Whereas the result obtained with IGF-binding protein alone is not significantly different from the control, a synergistic effect of the combination is seen when compared to IGF-I alone.

Further, the mitogenic activity of an IGF combined with a binding protein of the invention may be tested as follows: The incorporation of [<sup>3</sup>H] methylthymidine into CCL 39 cells (Chinese hamster lung fibroblasts) in culture is measured as described by Plouet et al. Cell. Mol. (1984) 30:105. In this assay, cell line CCI 39 is seeded in a plate at 40 000 cells per well in 0.5 ml MEM culture medium (Gibco) containing 10% fetal calf serum 0.1% penicillin, 0.4% streptomycin and 0.5% fungizone. After 72 hours incubation at 37°C in an atmosphere loaded with 5% CO<sub>2</sub>. Cells are washed with MEM medium in the absence of fetal calf serum and then cultured in this medium for 20 hours. At this stage, the cell culture is confluent and an IGF or a binding protein or both together are inoculated each at a dose of 10 ng to 200 ng culture medium. When added together the molar ratio must be 1:1. The test sample is incubated at 37°C for 24 hours and then added with 1  $\mu$ Ci [<sup>3</sup>H] methylthymidine in 10  $\mu$ l PBS. After 4 hours incubation the incorporation of methylthymidine is stopped washing cells with PBS. Cells are fixed with 0.5 ml trichloroacetic acid (5%) for 30 min. washed with



water and finally lysed with 0.5 ml of NaOH 0.1M for 2 hours at 37°C 0.5 ml of lysate is transferred into a scintillation flask and mixed with 3 ml of scintillation liquid for measuring  $\beta$ -radioactivity.

5 The binding protein potentiates the mitogenic activity of IGF although the radioactivity level that is measured when a binding protein is used alone is not substantially different from that of the control sample.

10 More particularly a binding protein of the invention, in combination with an IGF is useful  
a) for treating hypopituitarism. Laron-type dwarfism, osteoporosis, anemias especially complications following an chronic renal failure and liver or kidney  
15 deficiency and b) for promoting healing of wounds such as ulcers and burns or those occurring in accidental events or resulting from surgery.

For use in association with a binding protein of the invention. IGF is preferably selected from IGF-I  
20 as described in Rinderknecht, E. and Humbel, R.E., J. Biol. Chem. (1978) 253:2769. IGF-II as described in Rinderknecht, E. and Humbel, R.E., FEBS (1978) 89:283 and any derivative or fragment of IGF-I and IGF-II having an insulin-like growth factor activity. Most  
25 preferably, this is IGF-II.

For use in association with an IGF, a binding protein of the invention is preferably a protein which is from 85% to 100% homologous with pre IGF-BP or IGF-BP as shown in Figure 1.

30 When not associated with IGFs, binding proteins of the invention have further therapeutic applications in any physiological disorders resulting from an excessive production of free IGFsa, e.g. IGF-producing cancers such as breast or kidney cancer,  
35 diabetic proliferative retinopathy or abnormal growth of tall children with high serum level of free IGF.

Accordingly, the invention also provides:

---

(i) the use of a binding protein of the invention for treating physiological disorders resulting from an excessive production of free IGF by a mammalian, for example human body, e.g. IGF-producing cancers, diabetic retinopathy or abnormal growth of tall subjects, or

(ii) a method of treating physiological disorders resulting from an excessive production of free IGF, e.g. IGF-producing cancers, diabetic retinopathy or abnormal growth of a subject which comprises administering a therapeutically effective amount of a binding protein of the invention to a subject in need of such treatment, or

(iii) a pharmaceutical composition for treating physiological disorders resulting from an excessive production of free IGF, e.g. IGF-producing cancers, diabetic retinopathy or abnormal growth of a subject which comprises a binding protein of the invention in association with a pharmaceutically acceptable carrier or diluent, or

(iv) a method of delivering IGFs to specific organs or tissues based on the differential binding properties of IGFBP-5, as indicated by biological testing.

Fragments of mutated forms of the pre-IGF-BP or IGF-BP as shown in Figure 1 are of particular value for treating the physiological disorders resulting from an excessive production of free IGF in the human body.

A binding protein of the invention, alone or in combination with an IGF, may be administered by any conventional route suitable for peptides, or particular enterally, e.g. in the form of tablets or capsules or, preferably parenterally, e.g. subcutaneously or intravenously in the form of injections or infusions. Further, it may be also used topically, e.g. in the form of ointments or suspensions when used, e.g. as a wound healing agent.

For all the above indications the appropriate dosage will be course vary depending upon, for example, the nature and severity of the disorder to be treated and the mode of administration. For example, 5 satisfactory results may be obtained in the treatment of osteoporosis or anemia at daily dosages from about 0.1  $\mu\text{g/kg}$  to 40  $\mu\text{g/kg}$  body weight, preferably from about 0.5  $\mu\text{g/kg}$  to about 20  $\mu\text{g/kg}$  body weight of a binding protein of the invention. In larger mammals, 10 for example humans, as indicated daily dosage is from about 5  $\mu\text{g}$  conveniently administered parenterally, for example once a day. For wound healing, a daily dose of from 0.1 to 10  $\mu\text{g}$  of a protein of the invention per  $\text{cm}^2$  wound area is suitably indicated in larger mammals, for 15 example humans. This is conveniently administered once a day. When used in combination with an IGF, the molar ratio of the binding protein to IGF is preferably from 0.1:1 to 5:1, more preferably from 0.5:1 to 2:1, most preferably 1:1.

20 Pharmaceutical compositions of the invention may be manufactured in conventional manner.

Other uses for the binding proteins of the invention include various uses in the production of IGF molecules by recombinant techniques. The binding 25 proteins of the invention can be used to detect yeast-produced IGF in native (active) conformation (as opposed to inactivated forms). Additionally, the proteins of the invention can be used as carrier (possibly in the form of co-expressed proteins) in the 30 production of IGF. As the binding protein stabilized IGF in vivo, they are expected to do the same in vitro. The binding proteins can also be used to purify IGF produced in yeast by attaching them to a solid surface (such as in affinity chromatography).

35 While the invention has been described with reference to particular embodiments, methods, construction, and use, it will be apparent to those skilled in the art that various changes and modifi-

---

cations can be made without departing from the invention.

Example 1

5 Sepharose-IGF I affinity column

Sixty mg recombinant human IGF I (Ciba-Geigy AG, Basel, Switzerland) was dissolved in 20 ml 0.1 M  $\text{NaHCO}_3$ , pH 8.3, containing 0.5 M NaCl and coupled to CNBr-activated Sepharose 48 (4 g dry gel) according to the protocol of the supplier (Pharmacia Fine Chemicals, Uppsala, Sweden). The gel was equilibrated with 500 ml 0.05 M sodium phosphate buffer/0.5 M NaCl, pH 6.5, in a 1.5 x 15 cm glass column (gel bed volume 15 ml).

15

Purification of serum IGFBPs

This procedure was carried out according to a modification of the procedure of Martin and Baxter (18,19). Note that references shown in the examples in parentheses refer to the references listed by number in the Relevant Literature section of this specification. One liter of out-dated human citrate plasma was stirred for 2 hours at room temperature with 50 U (1 ml) thrombin-calcium, filtered through cheesecloth and acidified. Dissociated IGF was removed with SP-Sephadex C-25. The pH was subsequently adjusted to 6.5 and the precipitate removed by centrifugation at 20,000 rpm for 30 min. The supernatant was pumped through the Sepharose-IGF I affinity column described above at 34 ml/min and the column washed with 500 ml 0.05 M sodium phosphate buffer/0.5 M NaCl, pH 6.5. Binding protein (i.e., IGFBP) was eluted with 40 ml 0.5 M acetic acid, dialyzed 3 times against two liters of 0.1 M ammonium acetate, and lyophilized. The lyophilized material (40 mg) was dissolved in 4 ml 0.1 M heptafluorobutyric acid containing 20% (v/v) acetonitrile, and the insoluble material was removed by centrifugation at 10,000 for 10 min. The clear

supernatant was subjected to HPLC (2 runs with 2 ml each) on a Nucleosil C<sub>18</sub> column (Macherey-Nagel, Dren, FRG) (19). Effluent fractions were dried in a Speed-Vac (Savant Instruments, Hicksville, NY), taken up in 1 ml 0.01 M acetic acid, and dried again. The resulting material was dissolved in 250  $\mu$ l H<sub>2</sub>O for ligand blot analysis (see below) and silver staining (20).

#### <sup>125</sup>I-IGF ligand blot analysis

The method of Hossenlopp *et al.* (21) was used with slight modifications (6,19). Five- $\mu$ l aliquots of the HPLC effluent fractions were subjected to electrophoresis on 15% SDS polyacrylamide slab gels under nonreducing conditions. The <sup>14</sup>C-labeled molecular weight marker (Rainbow Marker, Amersham, UK) was reduced. The gels were transblotted on nitrocellulose membranes and processed as described (21). Membranes were incubated for 6 h at room temperature in a sealed plastic bag with 3 x 10<sup>6</sup> cpm <sup>125</sup>I-labeled IGF II (22). After several washes the air-dried membranes were exposed for 12-48 h at -70°C to an X-ray film (Kodak, X-OMAT, AR) in a Kodak X-OMATIC cassette (Eastman, Rochester, NY).

<sup>125</sup>I-IGF II was chosen as the tracer for screening because not all of the bands are detected with <sup>125</sup>I-IGF I (see results).

#### Electroblotting on polyvinylidene difluoride (Immobilion) membrane

Ten to thirty  $\mu$ g of HPLC-purified IGFBP was electrophoresed as described above (polyacrylamide slab gels 15x15x0.15 cm) under reducing conditions and electroblotted (2 h at 0.8 A) on an Immobilon membrane (Millipore Corp., Bedford, MA) as described by Matsudaira (23). The membrane was stained for 5 sec with 0.1% Coomassie Blue R-250 in 50% methanol, destained in 50% methanol/10% acetic acid for 5 min at room temperature, and then thoroughly rinsed in H<sub>2</sub>O.

The membrane was air-dried, and the protein bands were cut out and stored at -20°C.

Amino acid analysis was performed by automated Edman degradation using an Applied Biosystems Model 470A protein sequencer (Foster City, CA) (25).

#### Tissue and RNA isolation

Human osteosarcoma tissue was obtained from Dr. Marshall Urist, UCLA. Total RNA was isolated by the guanidinium thiocyanate method (27). An Osterizer was used to homogenize the tissue Poly(A)<sup>+</sup> RNA was purified by a single fractionation over oligo (dT) cellulose (29).

#### Oligonucleotide synthesis

Oligonucleotide adaptors, probes, and sequencing and PCR primers were synthesized by the phosphoramidite method with an Applied Biosystems (Foster City, CA) model 380A synthesizer, purified by polyacrylamide gel electrophoresis, and desalted on SEP-PAK C<sub>18</sub> cartridges (Waters; Milford, MA).

A 14-mer oligonucleotide (5' CCTGTAGATCT-CCG 3') and a 18-mer oligonucleotide (5' AATTCGGAGAT-CTACAGG 3') were synthesized and used as the EcoRI adaptors for the human osteocarcinoma cDNA library constructed in λZAP. The 14-mer was phosphorylated (30), then immediately heated to 95°C for 15 min to inactivate the polynucleotide kinase. The adaptors also contain an internal Bgl II site and are described more fully in the following section describing the construction of the cDNA library.

The two PCR primers for BP5 were: (1) a "sense" primer consisting of a mixture of 48 26-mers [5' AGATCTGAATTCGA(C/T)GA(A/G)GCXAT(A/T/C)CA 3'] and (2) an "antisense" primer consisting of a mixture of 64 26-mers [5' AGATCTGAATTCGC(T/C)A(G/A)(T/C)TTXG-C(T/C)TC 3'] where X denotes all four deoxynucleotides. Eco RI sites were included in the primers to allow for

subcloning into M13 sequencing vectors. The RP5 probe consisted of a 20-mer (5' TCGGAGCAGGGCGGGCAGTG 3') and a 7-mer primer (5' CACTGCC 3').

5     PCR amplification of BP5 sequences

          The PCR reactions were performed according to the supplier of the PCR kit (Perkin/Elmer/Cetus) using the PCR primers described (see Oligonucleotide Synthesis section) at a final concentration of 8  $\mu$ M.

10    The template cDNA was synthesized from 2.5  $\mu$ g of human osteosarcoma (Ost2) poly(A)<sup>+</sup> RNA. The conditions of cDNA synthesis were identical to those described below for first strand cDNA synthesis (see Construction of cDNA Library). The cDNA was fractionated on Biogel

15    A-15m, recovered by ethanol precipitation, and resuspended in 100  $\mu$ l of sterile water. From 2.5 to 5  $\mu$ l of cDNA template were used for each PCR reaction. Thirty-five cycles of PCR were performed in a Perkin/Elmer/Cetus DNA thermocycler. The first

20    10 cycles consisted of a 94°C, 1 min. denaturation step; a 40°C, 1 min. annealing step; and a 40°C, 1 min. extension step. The next 25 cycles consisted of a 94°C, 1 min. denaturation step; a 55°C, 1 min. annealing step; and a 72°C, 1 min. extension step. The final

25    extension step at the last cycle was 7 min. Samples were extracted once with phenol/chloroform/IAA (1:1:0.04), once with chloroform/IAA (24:1), recovered by ethanol precipitation, digested with EcoRI, and fractionated by electrophoresis on a 7% acrylamide,

30    1x TBE gel (30). DNA migrating between 40-70 b.p. was excised from the gel, purified by passage over an Elutip-d column, ligated to Eco-RI cut m13 mol8, and introduced into DH5aF' for DNA sequencing.

35    Construction of the cDNA library

          First-strand cDNA was synthesized from human osteosarcoma (Ost3) poly(A)<sup>+</sup> RNA as described (33), but with the following modifications: 10  $\mu$ g of poly(A)<sup>+</sup> RNA

---

was heated to 65°C for 3 min in 20  $\mu$ l 5 mM Tris-hydrochloride (pH 7.5), immediately placed on ice for 1 min, and then adjusted (at room temperature) to contain 50 mM Tris-hydrochloride (pH 8.3 at 42°C), 8 mM MgCl<sub>2</sub>, 30 mM KCl, 10 mM dithiothreitol, 2 mM each of dATP, dGTP, dTTP and [ $\alpha$ -<sup>32</sup>] dCTP (300 cpm/pmol), 60 U RNasin, and 2.5  $\mu$ g of oligo (dT)<sub>12-18</sub>. Sixty U of cloned moloney murine leukemia virus reverse transcriptase was added to initiate cDNA synthesis (total reaction volume 40  $\mu$ l), and the reaction was continued for 60 min at 42°C. The second cDNA strand was synthesized and ligated to the EcoRI adaptors (see Oligonucleotide Synthesis section) as described (34). The dscDNA was phosphorylated (30) and then adjusted to 0.5 M NaCl/25 mM EDTA and heated at 75°C for 15 min to inactivate the polynucleotide kinase. The dscDNA was separated from unligated adaptors by chromatography on Biogel A-15m and recovered by ethanol precipitation. The dscDNA was ligated to EcoRI-cut  $\lambda$ ZAP (Stratagene) as described by the supplier, but including 15% polyethylene glycol (PEG) 8000 (Sigma) in the reaction medium, a modification previously described (35). The ligated DNA was recovered by centrifugation (12,000 x g), washed with chloroform, dried, resuspended in 4  $\mu$ l H<sub>2</sub>O, and incubated with an in vitro packaging extract (Stratagene) according to the supplier. A library of  $2.3 \times 10^7$  independent recombinant clones was obtained. Recombinant phages were propagated in E. coli BB4 (Stratagene).

#### Screening of the cDNA library

Approximately 300,000 recombinant phages from the Ost3 cDNA library were plated (50,000 phages/137 mm dia. plate) in E. coli BB4 and grown for 5-6 hours at 37°C. The phages were transferred onto nitrocellulose filters (Millipore, HATF 137), processed (36), and screened with the BP4 or BP5 probes. The BP4 probe was labeled with T<sub>4</sub> polynucleotide kinase and [ $\gamma$ -<sup>32</sup>P] ATP



(28) to a specific activity of  $1-2 \times 10^8$  cpm/ $\mu$ g. The BP5 probe was labeled according to Feinberg and Vogelstein (42). The filters were prehybridized for 1-2 h at 37°C in 5 x SSC (1 SSC = 0.15 M sodium chloride/0.015 M sodium citrate, pH 7) 40% formamide, 5 x Denhardt's solution (1 x Denhardt's solution = 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), 10% dextran sulfate, 50 mM sodium phosphate, pH 6.8, 1 mM sodium pyrophosphate, 0.1% NaDodSO<sub>4</sub>, and 50  $\mu$ g/ml denatured salmon sperm DNA. Labeled probe was added to a concentration of  $10^6$  cpm/ml, and hybridization was continued overnight at 37°C with gentle shaking. The filters were washed in 2 x SCC/0.1% NaDodSO<sub>4</sub> at 65°C and exposed to Kodak XAR-2 films with a DuPont Lightning Plus intensifying screen overnight at -80°C. Areas of plaques giving duplicate signals were picked, replated, and rescreened until pure plaques were obtained.

Plasmid Isolation, Subcloning, and Sequencing

Bluescript SK(-) containing BP5 cDNA inserts were released from  $\lambda$ ZAP by the M13 rescue/excision protocol described by the supplier (Stratagene). Plasmid DNA was isolated by the alkaline lysis method (30). The inserts were excised from the Bluescript SK(-) vector by a Bgl II digestion and fractionated by agarose gel electrophoresis. Inserts were excised from the gel and passively eluted for 12 h with gentle shaking in 10 mM Tris-hydrochloride pH 7.5, 1 mM EDTA (TE), purified by elutip-D as described by supplier (Schleicher and Schuell), and subcloned into a M13 sequencing vector (37). DNA sequencing was performed by the dideoxy chain termination method (38) using M13 primers as well as specific internal primers. Ambiguous regions were resolved using 7-deaza-2-deoxyguanine-triphosphate (39) and sequenase (US Biochemicals).

20 Deposit of Genetic Information

The genetic sequences set forth in Figure 1 are on deposit with the American Type Culture Collection where they are identified as follows:

<u>25</u>	<u>Cloned Protein</u>	<u>Internal Identifier</u>	<u>In E. coli Strain</u>	<u>ATCC Number</u>
	IGFBP-5	pBsPB5.5	RR1 $\Delta$ M15	68387

## WE CLAIM:

1. A recombinant DNA molecule comprising a nucleic acid sequence encoding insulin-like-growth-factor binding protein 5 (IGFBP-5) or a subsequence thereof comprising at least 10 nucleotides.
  2. The recombinant DNA molecule of Claim 1, wherein said sequence is as set forth for IGFBP-5 in Figure 1.
  3. The recombinant DNA molecule of Claim 1, which comprises a human DNA sequence.
  4. The recombinant DNA molecule of Claim 1, wherein said sequence is a genomic sequence.
  5. The recombinant DNA molecule of Claim 1, wherein said sequence is a cDNA sequence.
  6. The recombinant DNA molecule of Claim 1, wherein said molecule is contained in pBSBP5.5.
  7. A recombinant microorganism or cell line containing the DNA molecule of Claim 1.
  8. The microorganism of Claim 7, wherein said microorganism is a yeast.
  9. The cell line of Claim 7, wherein said cell line is a CHO cell line.
  10. A method for producing IGFBP-5 or a fragment thereof comprising growing a recombinant host containing the DNA molecule of Claim 1 under conditions wherein said IGFBP-5 or fragment is expressed by the host and then isolating the expressed IGFBP-5 or fragment.
-

11. The method of Claim 10, wherein said host is a microorganism.

5 12. The method of Claim 10, wherein said host is a eucaryotic cell.

13. The method of Claim 10, wherein said host is a non-human transgenic animal.

10

---

1/4  
FIGURE 1

## DNA and Amino Acid Sequence of Clone Encoding hIGFBP-5

1  
 GAATTCGGAGCTCTACAGGGGTC ATG CTG CCC CTC TGC CTC GTG GCC GCC  
 Met Leu Pro Leu Cys Leu Val Ala Ala  
 10  
 Leu Leu Leu Ala Ala Gly Pro Gly Pro Ser Leu Gly Asp Glu Ala  
 CTG CTG CTG GCC GCC GGG CCC GGG CCG AGC CTG GGC GAC GAA GCC  
 20  
 Ile His Cys Pro Pro Cys Ser Glu Glu Lys Leu Ala Arg Cys Arg  
 ATC CAC TGC CCG CCC TGC TCC GAG GAG AAG CTG GCG CGC TGC CGC  
 30  
 Pro Pro Val Gly Cys Glu Glu Leu Val Arg Glu Pro Gly Cys Gly  
 CCC CCC GTG GGC TGC GAG GAG CTG GTG CGA GAG CCG GGC TGC GGC  
 40  
 Cys Cys Ala Thr Cys Ala Leu Gly Leu Gly Met Pro Cys Gly Val  
 TGT TGC GCC ACT TGC GCC CTG GGC TTG GGG ATG CCC TGC GGC GTG  
 50  
 Tyr Thr Pro Arg Cys Gly Ser Gly Leu Arg Cys Tyr Pro Pro Arg  
 TAC ACC CCC CGT TGC GGC TCG GGC CTG CGC TGC TAC CCG CCC CGA  
 60  
 Gly Val Glu Lys Pro Leu His Thr Leu Met His Gly Gln Gly Val  
 GGG GTG GAG AAG CCC CTG CAC ACA CTG ATG CAC GGG CAA GGC GTG  
 70  
 Cys Met Glu Leu Ala Glu Ile Glu Ala Ile Gln Glu Ser Leu Gln  
 TGC ATG GAG CTG GCG GAG ATC GAG GCC ATC CAG GAA AGC CTG CAG  
 80  
 Pro Ser Asp Lys Asp Glu Gly Asp His Pro Asn Asn Ser Phe Ser  
 CCC TCT GAC AAG GAC GAG GGT GAC CAC CCC AAC AAC AGC TTC AGC  
 90  
 Pro Cys Ser Ala His Asp Arg Arg Cys Leu Gln Lys His Phe Ala  
 CCC TGT AGC GCC CAT GAC CGC AGG TGC CTG CAG AAG CAC TTC GCC  
 100  
 Lys Ile Arg Asp Arg Ser Thr Ser Gly Gly Lys Met Lys Val Asn  
 AAA ATT CGA GAC CGG AGC ACC AGT GGG GGC AAG ATG AAG GTC AAT  
 110  
 Gly Ala Pro Arg Glu Asp Ala Arg Pro Val Pro Gln Gly Ser Cys  
 GGC GCG CCC CCG GAG GAT GCC CCG CCT GTG CCC CAG GGC TCC TGC  
 120  
 Gln Ser Glu Leu His Arg Ala Leu Glu Arg Leu Ala Ala Ser Gln  
 CAG AGC GAG CTG CAC CGG GCG CTG GAG CCG CTG GCC GCT TCA CAG  
 130  
 Ser Arg Thr His Glu Asp Leu Tyr Ile Ile Pro Ile Pro Asn Cys  
 ACC CGC ACC CAC GAG GAC CTC TAC ATC ATC CCC ATC CCC AAC TGC  
 140  
 Asp Arg Asn Gly Asn Phe His Pro Lys Gln Cys His Pro Ala Leu  
 GAC CGC AAC GGC AAC TTC CAC CCC AAG CAG TGT CAC CCA GCT CTG  
 150  
 160  
 170  
 180  
 190  
 200  
 210

Page 2 of 2

[illegible]

Translated Mol. Weight = 27938.61

\*MW. 25978.7.4 for remainder of protein

**FIGURE 2**

### Comparison of Various Human IGFBP Amino Acid Sequences

```

HBP-1  -28 M S E V P V A R V M L V L L L L T V Q V Q V T A S - - - - - - - - - - - - - - - -
HBP-2  -39 M L P R V Q C P A L P L P P P P L L P P L P L L L L L L Q A S Q S S Q Q A - A - A -
HBP-4  -27 M Q D A S P T I W A A A I T I I V I I D R P P V A D A - A A Q Q R A I R - - - - -
HBP-6
HBP-6

```

HP-1	1	A	P	W	C	A	P	C	S	A	R	L	L	C	-	P	P	V	S	-	-	-	-	-	-	-	A	S	S	
HP-2	2	V	L	F	C	P	P	C	T	P	R	L	A	A	C	P	P	V	A	P	A	A	V	A	V	A	A	P	G	E
HP-3	9	P	V	R	C	P	P	C	D	R	A	L	A	A	C	P	P	V	-	-	-	-	-	-	-	-	A	P	G	E
HP-4																														
HP-5		E	A	I	H	C			S	E	K	L	A	A	C	P	P	V	-	-	-	-	-	-	-	-	A	P	G	E

[illegible]

HSP-1 66 Q E L P L K A L T V N G Q Q G A C V Q E S D A S - - - - - A - P H A  
 HSP-2 68 E L P L Q A L L Y M G G G T C C K N R A D A Y - - - - - A - S S E  
 HSP-3 74 A R A P L Q A L L D G R G L C V N A A P E - - - - - A - S S E  
 HSP-4 Q E L P L Q A L L D G R G L C V N A A P E - - - - - A - S S E  
 HSP-5 Q E L P L Q A L L D G R G L C V N A A P E - - - - - A - S S E

[illegible][illegible][illegible]

NBP-1	186	S	M	D	G	K	A	B	L	C	M	G	V	Y	P	N	H	G	K	L	I	P	Q	S	P	E	I	R	D	P	N	C	I	L	Y	F	N	V	Q	M
NBP-2	239	S	L	H	G	K	A	B	L	C	M	G	V	Y	P	N	H	G	K	L	I	P	Q	S	P	E	I	R	D	P	N	C	I	L	Y	F	N	V	Q	M
NBP-3	327	S	K	R	R	K	A	B	L	C	M	G	V	Y	P	N	H	G	K	L	I	P	Q	S	P	E	I	R	D	P	N	C	I	L	Y	F	N	V	Q	M
NBP-4		S	K	R	R	K	A	B	L	C	M	G	V	Y	P	N	H	G	K	L	I	P	Q	S	P	E	I	R	D	P	N	C	I	L	Y	F	N	V	Q	M
NBP-5		S	L	D	G	K	A	B	L	C	M	G	V	Y	P	N	H	G	K	L	I	P	Q	S	P	E	I	R	D	P	N	C	I	L	Y	F	N	V	Q	M

REP-1  
REP-2 279 E A R O V H T Q A M Q  
REP-3  
REP-4  
REP-5



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 91/06140

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): C07K 3/00; C07H 15/12; C12P 21/06		
U.S.C1.: 530/350; 536/27; 435/69.1		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S. C1.	530/350; 536/27; 435/69.1	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
APS DIALOG FILES 5,155, 50, 73, 144 149, 76 Sequence		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y,P	Molecular Endocrinology, Volume 4, No. 1, issued December 1990, Lafoun et al., "Inhibitory insulin-like growth factor-binding protein: cloning, complete sequence, and physiological regulation." pages 100-114, see Abstract No. 6/90/1000.	1-12
Y	The EMBO Journal, volume 3, No. 1, issued February 1984, Ulrich et al., "Isolation of the human insulin-like growth factor I gene using a single synthetic DNA probe", pages 301-4 see entire document.	1-5
<p>* Spec. categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22 October 1991	18 DEC 1991	
International Searching Authority	Signature of Authorized Officer	
ISA/US	H. Sidberry	

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Proceeding of the National Academy of Science, vol. 86, issued November 1989, Mohan et al., "isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: A potential local regulation of IGF action." Pages 8338-8342, see entire article.	1-5
Y	Molecular Endocrinology, volume 4, No. 10, issued 1990, Shimazaki et al., "Molecular Cloning of the cDNAs Encoding a Novel Insulin-like Growth Factor-Binding Protein From Rat and Human", Pages 1451-1458, see entire article.	1-13
Y	EP.A, 0,369,943 (Binkert et al.) 23 May 1990. See entire document.	1-5